Loss of Heterozygosity at 1p36 Independently Predicts for Disease Progression But Not Decreased Overall Survival Probability in Neuroblastoma Patients: A Children’s Cancer Group Study - Wikidata - wikimedia - TriplyDB

Loss of Heterozygosity at 1p36 Independently Predicts for Disease Progression But Not Decreased Overall Survival Probability in Neuroblastoma Patients: A Children’s Cancer Group Study

Loss of Heterozygosity at 1p36 Independently Predicts for Disease Progression But Not Decreased Overall Survival Probability in Neuroblastoma Patients: A Children’s Cancer Group Study

http://www.wikidata.org/entity/Q57262599

about

Retinoic acid post consolidation therapy for high-risk neuroblastoma patients treated with autologous hematopoietic stem cell transplantation A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites Expression of SMARCF1, a truncated form of SWI1, in neuroblastoma Energy metabolism in neuroblastoma and Wilms tumor Unveiling MYCN regulatory networks in neuroblastoma via integrative analysis of heterogeneous genomics data.11q deletion in neuroblastoma: a review of biological and clinical implications.Research progress of neuroblastoma related gene variations.Paediatric urological malignancies.Neuroblastoma tumour genetics: clinical and biological aspects.Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future Clinical significance of NTRK family gene expression in neuroblastomas Mechanisms of CHD5 Inactivation in neuroblastomas.Experience with International Neuroblastoma Staging System and Pathology Classification.Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project.CAMTAs: calmodulin-binding transcription activators from plants to human.The MYCN oncogene is a direct target of miR-34a.Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction.Management and outcome of stage 3 neuroblastoma.Role of microRNAs in epigenetic silencing of the CHD5 tumor suppressor gene in neuroblastomas.Presence of 1q gain and absence of 7p gain are new predictors of local or metastatic relapse in localized resectable neuroblastoma.Genetic stratification of neuroblastoma for treatment tailoring.Neuroblastoma: the impact of biology and cooperation leading to personalized treatments.Distinct cytogenetic pathways of advanced-stage neuroblastoma tumors, detected by spectral karyotyping.Retinoic acid postconsolidation therapy for high-risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation.Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations.Biological significance of EPHA2 expression in neuroblastoma.Homozygous deletion in a neuroblastoma cell line defined by a high-density STS map spanning human chromosome band 1p36.Clinical evaluation of integrated panel testing by next-generation sequencing for somatic mutations in neuroblastomas with MYCN unamplification.Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.Region-specific detection of neuroblastoma loss of heterozygosity at multiple loci simultaneously using a SNP-based tag-array platform.Knowing your ABCCs: novel functions of ABCC transporters.Evolving significance of prognostic markers associated with treatment improvement in patients with stage 4 neuroblastoma.Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification.ALK Gene Copy Number Gain and Immunohistochemical Expression Status Using Three Antibodies in Neuroblastoma.High-dose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk neuroblastoma patients.Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma

P2860

Q24186451-D68A9AF6-2509-4DE9-A46E-6DD5B5B84F33 Q24603988-FD51EFE6-9BB0-45CA-A748-450DEB2B1E1E Q24685907-1D2CE8FA-380E-44CF-BB35-7BECBA64D5DA Q26770341-01EADF95-347A-4A76-91A4-0F94F753A2D2 Q31095310-3F547DB5-C4E4-4BE9-82E5-892018AC6B1B Q32174267-CC5B5C39-75E2-4816-8856-210D46176F3C Q33566987-3A0AA0EC-87DE-4D13-9F8D-89DFF07F3506 Q34249635-D6976DD3-6D1D-4EE0-9D4E-DFF76449B5E6 Q34453849-616AB8D4-2E1C-43CC-9500-74A1FEACBE4A Q35108252-C19138F6-4D07-4FDE-A4B6-0C8328D6F12A Q35673178-AECAAD69-5A8C-40F6-994C-A9BE20E6B82B Q35836491-AB72C212-D6B5-4002-937C-51B48E3D539C Q36623808-76E8EF69-9DA3-43DF-A253-55881F8F0711 Q36649728-94A26103-F9CB-498C-8098-DBE3DC70998C Q36906282-C4BCDF55-F916-4834-AA2E-E9D62A0D9F54 Q36926506-CCE49D6C-909E-4DD0-919E-AC42F1B9A441 Q36944205-A9EEEAE9-6301-4491-818D-9CC0A3C8633B Q37056086-32859B93-4F68-4283-89A1-B5A36A94278C Q37085930-1FFE9A27-E4C0-4E03-8C1C-07316AAD9CCE Q37284320-3CF9A785-BB17-4643-A96F-FAC39C12A10B Q37932545-905A7B11-EC5C-433B-8776-95836075A8B4 Q38014527-CC76F2A5-21C5-46F8-A1FE-90AFBF25709E Q38489272-25BB5066-6612-4A47-BFD3-329CCF7CCBED Q38608663-58F5BDB6-99CF-44DD-9EEC-EE2353852E25 Q38625880-AB2D1C34-D07E-4085-B2CE-B1A514D28A18 Q39227009-F4F5DD1C-9062-4AC6-B722-23143F034788 Q40795397-615153B2-CC21-4C72-8FEC-A237A3FEEBA0 Q41472684-49A54937-BA16-467A-B07E-47AC663FF819 Q41842569-4686810C-6264-4BCA-8E07-8B20761CA440 Q41883212-5773C115-B2B5-4EC4-85B7-D7EE215B06B8 Q41959730-491CDFAF-0869-427E-AFBA-9780FE347C00 Q42869009-0C5DCE78-DCD3-4E2E-898C-AC2C5FB22A19 Q44098566-E465DCBB-F983-4570-A441-E78D973565A4 Q46527475-00CB5583-AFA8-4219-A7C8-C151F5A86CEE Q51091340-C04302C0-0B7D-440A-8251-E7CDB6E38C90 Q53269806-FC6CDB8F-CE09-4051-9CE0-0E29BB626C2B Q58698690-B17A3498-D394-4693-AA30-1061440B157A

P2860

Loss of Heterozygosity at 1p36 Independently Predicts for Disease Progression But Not Decreased Overall Survival Probability in Neuroblastoma Patients: A Children’s Cancer Group Study

http://www.wikidata.org/entity/Q57262599

description

article

@en

im Mai 2000 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в травні 2000

@uk

name

Loss of Heterozygosity at 1p36 ...... Children’s Cancer Group Study

@en

Loss of Heterozygosity at 1p36 ...... Children’s Cancer Group Study

@nl

type

label

Loss of Heterozygosity at 1p36 ...... Children’s Cancer Group Study

@en

Loss of Heterozygosity at 1p36 ...... Children’s Cancer Group Study

@nl

altLabel

Loss of heterozygosity at 1p36 ...... Children's Cancer Group study

@en

prefLabel

Loss of Heterozygosity at 1p36 ...... Children’s Cancer Group Study

@en

Loss of Heterozygosity at 1p36 ...... Children’s Cancer Group Study

@nl

P1433

Q57262599-550ECF71-0F21-4B61-9FA9-4A9B0FF7D862

P1476

Q57262599-9F0B7176-4F18-4155-ACD0-A24008FBEF33

P2093

Q57262599-2114E5B5-8C24-447C-A5E9-A94E6B506DC1

Q57262599-23C3FA31-6A37-4947-9C48-C462689A6DE5

Q57262599-5342D663-DB05-4D3D-BEF3-D249304D853E

Q57262599-763AEA21-EF85-48D6-862F-6725D5667336

Q57262599-92799712-71D9-4E16-9C06-AA47BA065479

Q57262599-939F60F5-DFD4-4977-ABCC-1420F3C9529D

Q57262599-ACA11C31-ED17-4BFF-B4F5-B2B3A8F1112B

Q57262599-B270A2D5-8481-4E46-A86E-07E6E0E7DF24

Q57262599-B3EBE3C0-7867-455A-849E-E6A52263474A

Q57262599-B6EBB469-31BC-4961-A21C-98BD5F067ADE

P304

Q57262599-A81CBA16-503E-4C0C-93B0-940719C37D18

P31

Q57262599-6667571C-862B-474E-8EFB-7F27A9A96AC1

P356

Q57262599-2898C02C-EF6A-47E0-A3CD-B70F30612B34

P407

Q57262599-060C41C5-D3AE-4A5F-84E0-08EC3A6F7FB7

P433

Q57262599-3F28DEDC-8704-47AD-8DEB-439A875EDD5E

P478

Q57262599-B8451671-D636-4E1F-966D-DDA195B0E333

P577

Q57262599-CBAD05A5-0292-4BF4-A7B3-F8DC2F8884AE

P698

Q57262599-D9A0BD57-9BB5-4880-B4D1-8139110A9AD6

P921

Q57262599-0B699980-F48B-4E20-94EE-40C4712950D1

P356

JCO.2000.18.9.1888

P1433

Journal of Clinical Oncology

P1476

Loss of Heterozygosity at 1p36 ...... Children’s Cancer Group Study

@en

P2093

Chun Guo

http://www.w3.org/2001/XMLSchema#string

Daniel O. Stram

http://www.w3.org/2001/XMLSchema#string

Erik P. Sulman

http://www.w3.org/2001/XMLSchema#string

Garrett M. Brodeur

http://www.w3.org/2001/XMLSchema#string

John M. Maris

http://www.w3.org/2001/XMLSchema#string

John N. Lukens

http://www.w3.org/2001/XMLSchema#string

Katherine K. Matthay

http://www.w3.org/2001/XMLSchema#string

Matthew J. Weiss

http://www.w3.org/2001/XMLSchema#string

Michael D. Hogarty

http://www.w3.org/2001/XMLSchema#string

Patricia M. Thompson

http://www.w3.org/2001/XMLSchema#string

P304

1888-1899

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2000.18.9.1888

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2000-05-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

10784629

http://www.w3.org/2001/XMLSchema#string

P921